StockData
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX) stock

RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/309% below fair value
$2.72−0.18 (-6.37%)

Close on Nov 17, 2026Market cap $1.46BP/E –Yield –

Recursion Pharmaceuticals price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Recursion Pharmaceuticals's price to book ratio was 2.1× on Nov 11, 2026, against 2.2× a year earlier. Over the last 5 years it ranged from 1.4× to 6.8×, with a median of 3.0×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.1×+0.2
2025Dec 31, 20251.9×−1.8
2024Dec 31, 20243.7×−1.2
2023Dec 29, 20234.9×+1.4
2022Dec 30, 20223.5×−1.4
2021Dec 31, 20214.8×–

More Recursion Pharmaceuticals figures

See a number that looks wrong?